Livatag (doxorubicin transdrug) / Valerio Therap - LARVOL DELTA

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting (Cancer Chemother Pharmacol) - P=NA, N=60; Median PFS and OS were 2.4 months (2.0-2.8 months) and 6.1 months (4.2-8.0 months), respectively; The 6- and 12-month SR were 50.4 and 26.4%, respectively

Clinical data • Pancreatic Cancer

Neoadjuvant treatment for triple-negative breast cancer (OncLive) - "Hope S. Rugo, MD: It’s actually fascinating because now we’re in another quandary. But the biggest trial is KEYNOTE-522, and that trial is really important because it shows our change in thinking. We want to do trials in the neoadjuvant setting evaluating new drugs that are powered by event-free survival [EFS], so it has almost 1200 patients....Joyce A. O’Shaughnessy, MD: Yeah. It was significant for survival. One was significant, 1 was not small numbers but very encouraging for the triple-negative and for the PD-L1-positive, I thought."

Video

Immunotherapy comes of age in breast cancer (OncLive) - "'When IL-2 and interferon were being tested for melanoma and renal cell [carcinoma] the word on the street was that your body doesn’t see breast cancer cells as being foreign because you have breast cancer cells floating about anyway,' said Hope S. Rugo...'With longer follow up the survival improvement in patients who had IC+ disease was 7 months, very impressive,' said Rugo....Future directions for the field include looking at novel combination strategies that may offer great promise. Explorations into benefit for HER2-positive and estrogen receptor–positive disease are also being actively explored. 'Immunotherapy is a reality now for breast cancer,' Rugo concluded."

Media quote

Immunotherapy continues to show promise in TNBC (OncLive) - "Nearly 1 year following the first checkpoint inhibitor approval in advanced triple-negative breast cancer, additional immunotherapeutic agents are poised to enter the field, according to Rita Nanda, MD....In an interview...Nanda...discussed ongoing advances with immunotherapy in TNBC, as well as develops in the HER2-negative breast cancer paradigm....We will be getting more data regarding immunotherapeutic agents in the neoadjuvant space. Data from the NeoTRIPaPDL1 trial will hint as to whether we can drop anthracyclines in the setting of platinum- and taxane-based therapy for patients with early-stage TNBC."

Interview

ReLive: Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - P3; N=398; Completed; Sponsor: Onxeo; Active, not recruiting ➔ Completed

Clinical • Trial completion

Matulonis highlights novel strategies, emerging agents in ovarian cancer (OncLive) - "It is important for both oncologists, as well as women who have ovarian cancer, to just be aware of the various clinical trials that are ongoing. There is a great magnitat are testing very exciting agents. We are thinking about patients’ ovarian cancer histology—whether it’s high-grade serous, low-grade serous, mucinous, or clear cell....For example, low-grade serous carcinoma can be quite sensitive to hormonal therapies. Therefore, it’s important for physicians to look at the pathology report."

Media quote

NRG Oncology Semiannual Meeting - "Thursday, February 7, 2019, 4:35-4:50PM, Project Team Member Applications:U- nderstanding PTMA; February 8-9, 2019, 8:00 am - 10:00 am, Review of Active Studies: NRG-GY009 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and Atezolizumab vs Pegylated Liposomal  Doxorubicin/Bevacizumab and Atezolizumab vs Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer; Saturday, February 9, 2019; 10:00 AM – 12:00 PM, Gynecologic Cancer Workshop Committee; Chair: Carol Aghajanian, MD."

CME